Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H16N9O5S3.Na |
| Molecular Weight | 533.54 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C([O-])=O
InChI
InChIKey=RXYOYKDBLLALFG-FAIYLGIWSA-M
InChI=1S/C16H17N9O5S3.Na/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7;/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29);/q;+1/p-1/b21-8-;/t9-,13-;/m1./s1
Cefmenoxime is a semisynthetic beta-lactam cephalosporin antibiotic with activity similar to that of cefotaxime. Like other 'third-generation' cephalosporins it is active in vitro against most common Gram-positive and Gram-negative pathogens, is a potent inhibitor of Enterobacteriaceae (including beta-lactamase-producing strains), and is resistant to hydrolysis by beta-lactamases. Cefmenoxime has a high rate of clinical efficacy in many types of infection and is at least equal in clinical and bacteriological efficacy to several other cephalosporins in urinary tract infections, respiratory tract infections, postoperative infections and gonorrhoea. The bactericidal activity of cefmenoxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefmenoxime is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases. Cefmenoxime is marketed in Japan under the brand name Bestron, indicated for the treatment of otitis externa, otitis media, and sinusitis. Cefmenoxime hydrochloride was approved by the U.S. Food and Drug Administration (FDA) on Dec 30, 1987. It was developed and marketed as Cefmax®, but it has being discontinued.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | BESTRON Approved UseINDICATIONS
Launch Date1996 |
|||
| Curative | BESTRON Approved UseINDICATIONS
Launch Date1996 |
|||
| Curative | BESTRON Approved UseINDICATIONS
Launch Date1996 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
88.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6098220 |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFMENOXIME plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
95.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6098220 |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFMENOXIME plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
84 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6095752 |
15 mg/kg bw single, intravenous dose: 15 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFMENOXIME serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6098220 |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFMENOXIME plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6098220 |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFMENOXIME plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6095752 |
15 mg/kg bw single, intravenous dose: 15 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFMENOXIME serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
23% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6098220 |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFMENOXIME plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
23% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6098220 |
10 mg/kg bw single, intravenous dose: 10 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFMENOXIME plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
150 mg/kg 1 times / day multiple, intravenous Studied dose Dose: 150 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 150 mg/kg, 1 times / day Sources: |
unhealthy, 1-15 years |
|
12 g 1 times / day multiple, intravenous Studied dose Dose: 12 g, 1 times / day Route: intravenous Route: multiple Dose: 12 g, 1 times / day Sources: |
unhealthy, 55.5 years (range: 19-88 years) n = 2 Health Status: unhealthy Condition: intra abdominal infection Age Group: 55.5 years (range: 19-88 years) Sex: M+F Population Size: 2 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. | 1981 Jan |
|
| Therapeutic efficacy of chloramphenicol, co-trimoxazole (trimethoprim/sulphamethoxazole), cefmenoxime and ceftriaxone in experimental bacteraemia and meningitis caused by ampicillin-resistant Haemophilus influenzae type b. | 1988 Nov |
|
| Cefmenoxime in corneal organ culture. | 1994 |
|
| Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. | 1994 Mar |
|
| [Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis]. | 1995 May |
Sample Use Guides
Dissolve the powder in the attached solvent at a final
concentration of 10 mg (potency)/1 mL as cefmenoxime
hydrochloride, and used as follows:
For otitis externa and otitis media, usually instill 6 to 10 drops
into the ear and keep the same position for about 10 minutes
twice daily.
For sinusitis, usually inhale nasally by a nebulizer 2 to 4 mL
every other day, 3 times per week or inject 1 mL into the
maxillary sinus once per week.
The frequency of administration may be adjusted depending
on the patient’s symptoms.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
RB30TNF2RT
Created by
admin on Sat Dec 16 10:43:03 GMT 2023 , Edited by admin on Sat Dec 16 10:43:03 GMT 2023
|
PRIMARY | |||
|
23676080
Created by
admin on Sat Dec 16 10:43:03 GMT 2023 , Edited by admin on Sat Dec 16 10:43:03 GMT 2023
|
PRIMARY | |||
|
65085-02-1
Created by
admin on Sat Dec 16 10:43:03 GMT 2023 , Edited by admin on Sat Dec 16 10:43:03 GMT 2023
|
PRIMARY | |||
|
m3196
Created by
admin on Sat Dec 16 10:43:03 GMT 2023 , Edited by admin on Sat Dec 16 10:43:03 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD
